

November 8, 2018

Company Name: HEALIOS K.K.
Representative: Hardy TS Kagimoto, Chairman & CEO
(TSE Mothers Code: 4593)

Management team of Organoid Neogenesis Laboratory Inc.

HEALIOS K.K. established its subsidiary, Organoid Neogenesis Laboratory Inc. (“ONL”), in June 2018 to promote the practical use of organ buds, a platform technology involving the use of 3D vascularized organ anlagen in the treatment of various diseases, including those of the liver.

We are pleased to announce that the inventors of the technology, Professors Hideki Taniguchi and Takanori Takebe, have both taken on the role of director of ONL, which will strengthen the management of ONL and move the technology forward towards practical application.

Under the leadership of Professors Taniguchi and Takebe, ONL’s plans include: conducting pre-clinical studies to acquire proof of concept for currently planned pipeline organs and diseases; working towards the discovery of new pipeline candidates for additional organs and diseases; performing leading research in the field of drug screening; and further, seeking new inventions through discovery research.

Contact:
Corporate Communication Group
pr@healios.jp